Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This refers to a commercial measles, mumps, and rubella (MMR) vaccine being evaluated in a Phase 4 clinical trial (NCT07195032) sponsored by Children's Mercy Hospital Kansas City. The study investigates the safety and efficacy of the live attenuated vaccine in pediatric heart transplant recipients aged 12 months to 17 years. While MMR vaccines are standard for healthy children, they are typically contraindicated in immunocompromised patients, such as transplant recipients on immunosuppressive therapy. This trial aims to determine if vaccination can be safely performed and provide protective immunity in this high-risk population. The vaccine is a trivalent biologic containing live attenuated strains of the measles, mumps, and rubella viruses, designed to stimulate active immunity through the production of neutralizing antibodies and cellular immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on measles, mumps, and rubella vaccine-Children's Mercy Hospital Kansas City-measles-mumps-rubella.